Clinical Performance Evaluation of a Diagnostic Ultrasound System

NCT07066449 · tracked via the Priya Life Science China tracker

Sponsor

GE Healthcare

Phase

Observational

Started

2025-08-12

Last updated

2025-09-19

Condition(s) studied

Echocardiography

Study summary

Subjects who are required to undergo transesophageal echocardiography according to the current clinical practice standards will be eligible for enrollment. Subjects will be screened for enrollment in this study against the inclusion and exclusion criteria. After successful screening and enrollment of subjects, the investigators will first use the investigational device to conduct transthoracic echocardiography (TTE), followed by transesophageal echocardiography (TEE). TEE will be conducted after the subject has been anesthetized. To avoid any delay in diagnosis and treatment, after the scan with the investigational device is completed, the probe will be reserved and the console will be switched to the existing commercial cardiac diagnostic ultrasound device in the study site for intraoperative guidance. In the study, each investigator will evaluate the overall image quality, user interface, workflow, user preferences, product preset, and functions of the system, as well as the device's safety and stability and fill out a user feedback questionnaire provided by the Sponsor.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Adults ≥ 18 years old, have autonomous capacity; 2. Subjects who are required to undergo intraoperative transesophageal echocardiography according to the current clinical practice standards; 3. Agree to participate in this study and have signed the subject Informed Consent Form. Exclusion Criteria: 1. Subjects who have been previously enrolled in this study or are participating in other clinical trials; 2. Subjects with any medical emergency condition requiring urgent treatment; 3. Pregnant females; 4. Subjects with absolute contraindications of TEE (congenital or acquired upper digestive tract diseases, such as active upper gastrointestinal hemorrhage, esophageal obstruction or stenosis, esophageal tumor, esophageal lacerations and perforations, esophageal diverticula) or relative contraindications (changes in consciousness or lack of cooperation, history of cervical and mediastinal radiotherapy, history of recent esophageal surgery, esophageal varicosity, clotting disorders, cervical disease and injury, active esophagitis, active gastrointestinal ulcers, hiatal hernia, poor cardiopulmonary function, airway damage, pharyngeal space-occupying lesions, etc.), who are expected to be at high risks; 5. Any other subjects who should not participate in this study in the investigator's opinion.

Primary outcome measure(s)

The main evaluation indicators include Overall system operation, Reliability, System operability, Overall image quality, etc., and the evaluation results are represented by five grades: Excellent, Very good, Good, Bad, and Very bad. — From enrollment to Day 1 （Visit 1）

Trial sites (1)

Facility	City	Region	Status
Nanjing First Hospital, Nanjing Medical University	Nanjing	China	Recruiting

Other trials for the same condition

A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography Recruiting

Echocardiography Guided TAVR (Echo TAVR) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07066449 on ClinicalTrials.gov ↗ ← All trials in China